The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GHRS | +63.5% | N/A | N/A | -24% |
| S&P | +12.33% | +84.73% | +13.06% | +57% |
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.09M | -12.7% |
| Market Cap | $887.00M | 154.8% |
| Market Cap / Employee | $17.74M | 0.0% |
| Employees | 50 | 2.0% |
| Net Income | -$14.02M | -15.7% |
| EBITDA | -$16.45M | -31.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $249.65M | 177.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.22M | -52.6% |
| Short Term Debt | $0.37M | 32.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -17.11% | 2.1% |
| Return On Invested Capital | -11.62% | 11.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$14.48M | -13.8% |
| Operating Free Cash Flow | -$14.44M | -13.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.92 | 3.21 | 2.44 | 2.93 | 67.02% |
| Price to Tangible Book Value | 1.92 | 3.21 | 2.44 | 2.93 | 67.02% |
| Enterprise Value to EBITDA | -16.78 | -27.56 | -31.85 | -36.43 | 129.90% |
| Return on Equity | -19.6% | -16.2% | -16.3% | -17.9% | -10.54% |
| Total Debt | $0.62M | $0.66M | $0.65M | $0.58M | -20.60% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
